Propanc and FyoniBio Collaborate to Establish and Validate LC-MS-Based Pharmacokinetics Assay for PRP
Propanc, a biopharmaceutical company focused on developing novel treatments for chronic diseases, and FyoniBio, a German expert in clinical bioanalysis, have entered into a service agreement to establish and validate a liquid chromatography–mass spectrometry (LC-MS) based pharmacokinetics assay for Propanc’s lead product candidate, PRP.
This assay represents a key step in supporting the upcoming Phase 1b First-in-Human study, enabling precise quantification of PRP and its analytes in patients with advanced solid tumors.